Eli Lilly (LLY) Q2 2025 earnings report

Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business….

Read More

Trump’s drug price ultimatum sets pharma firms scrambling

A variety of generic pills and capsules.  Nenov | Moment | Getty Images Pharmaceutical firms are scrambling to respond to a fresh ultimatum from U.S. President Donald Trump demanding “binding commitments” to lower their drug prices stateside. The White House said Thursday that President Trump had sent letters to 17 major pharmaceutical firms outlining the…

Read More

Moderna (MRNA) Q2 2025 earnings

Moderna logo is seen in Warsaw, Poland on April 9, 2025. Jakub Porzycki | Nurphoto | Getty Images Moderna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street’s expectations for the second quarter as it works to cut costs….

Read More